DexCom (DXCM)
Add to Watchlists Create an AlertDXCM Key Stats
| Income Statement | |
| Revenue TTM | 109.40M |
| Revenue Quarterly YoY Growth | 47.26% |
| EPS Diluted TTM | -0.7424 |
| EPS Diluted Quarterly YoY Growth | |
| Net Income TTM | -51.54M |
| Profitability | |
| Gross Profit Margin Quarterly | 55.74% |
| Profit Margin Quarterly | -37.50% |
| Dividend | |
| Dividend Yield | 0.00% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 1.435B |
| Enterprise Value | 1.397B |
| PE Ratio TTM | |
| PE 10 Pro | Go Pro |
| PEG Ratio | |
| Price / Book Value | 19.50 |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | 0.0951 |
| Free Cash Flow | -5.90M |
| Return on Equity | -61.10% |
DXCM News
- DexCom Stays at Neutral - Analyst Blog Zacks May 23
- DexCom Stays at Neutral May 23
- Nasdaq stocks posting largest percentage increases May 20
- Medical Products Companies, Particularly Those Aimed at Surgical Procedures, Gen... May 17
- DexCom's Management Presents at Bank of America Merrill Lynch 2013 Health Care C... May 16
- 5 Stocks This Growth-Oriented Hedge Fund Is Most Committed To May 12
- DexCom Announces Upcoming Presentations Business Wire May 9
- 2 Winners and 3 Losers from This Week’s Earnings Storm May 4
- DexCom Loss Narrower than Est. May 2
- DexCom Loss Narrower than Est. - Analyst Blog Zacks May 2
DXCM Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). DexCom is up 93.52% over the last year vs S&P 500 Total Return up 27.77%, Medtronic up 41.87%, and Abbott Laboratories up 30.48%.
DXCM Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Cash Flow Statement View Statement
You may also be interested in these DXCM related companies
Pro Ratings for DXCM
Pro Report PDF for DXCM
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.
Download DXCM Pro Report PDF
Pro Strategies Featuring DXCM
Did DexCom make it into our Pro Portfolio Strategies?
DXCM Profile
Sector: Healthcare
Industry: Medical Instruments & Supplies
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes, and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. The company was founded by John F. Burd in May 1999 and is headquartered in San Diego, CA.
Other DXCM Resources
- Company Website
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| DXCM | 20.30 | +0.03 | +0.15% | 1.435B |
